U.K., Denmark, Iceland all go for Boehringer Ingelheim COPD drug Striverdi Respimat

Boehringer Ingelheim has gotten approval in the U.K., Denmark and Iceland for Striverdi Respimat. The new COPD therapy is a successor to its $4.7 billion-a-year Spiriva franchise. The drug has not yet been approved in the U.S; an FDA panel recommended it but said Striverdi has little to set it apart from COPD treatments already on the market. The FDA is expected to approve it, but some analysts wonder how it will fare if a generic of GlaxoSmithKline's ($GSK) Advair makes it to the market. Story | More